BTIG analyst Mark Massaro maintained a Buy rating on Castle Biosciences (CSTL – Research Report) yesterday and set a price target of $30.00. The company’s shares closed yesterday at $15.84.
Massaro covers the Healthcare sector, focusing on stocks such as Castle Biosciences, Exact Sciences, and Guardant Health. According to TipRanks, Massaro has an average return of -5.6% and a 38.12% success rate on recommended stocks.
Currently, the analyst consensus on Castle Biosciences is a Strong Buy with an average price target of $34.75.
See today’s best-performing stocks on TipRanks >>
Based on Castle Biosciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $42.04 million and a GAAP net loss of $29.2 million. In comparison, last year the company earned a revenue of $26.85 million and had a GAAP net loss of $24.58 million
Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CSTL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
Read More on CSTL:
- Craig-Hallum says CareDx appears to look to Congress for help amid Castle reversal
- Castle Biosciences management to meet with BTIG
- Castle Biosciences director sells $1.02M in common stock
- Castle Biosciences stock up amid ADLT status for DecisionDx-SCC, says KeyBanc
- Castle Bio (NASDAQ:CSTL) Skyrockets after Novitas Drops Key Coverage Proposal
